Topic summary

Research-use-only labelling: what it means and what it does not — the long version

Sourcing › Regulatory EMA research use only compounding

This is a generated summary. It shows the 9 most-liked posts from a topic of 159, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

KForsbergTL2Member26 Sep 2024#4

Nothing in this subcategory is legal advice, and the members who work in regulated environments are the most careful to say so.

The claim is narrower than it sounds, and deliberately so.

31 likes 22mo

r.aldana_pharmdTL4Pharmacist13 Nov 2024#26

Answering the question post #24 raises rather than the one it answers.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

A qualification I should have led with rather than closed on.

28 likes 20mo

stopper_traceTL2Member16 Dec 2024#45

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

Take it as a starting point and not as a specification.

29 likes 19mo

TavaresTL1Member7 Jan 2025 · edited#59

This settles it for me, at least until somebody posts a reason it should not.

28 likes 19mo

orbitrap_olaTL3Mass spectrometrist20 Feb 2025#89

b.wikstrom, post #88: If you can confirm or contradict a position for your own region, please date the answer. An undated regional claim is the least useful thing in this category. If the premise is wrong, everything after it is decoration. Go to post

That is clearer than the version I had in my head. Thank you.

32 likes in reply to #88 17mo

a.amankwahTL218 Mar 2025#108

On Research-use-only labelling I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

29 likes 16mo

h.oyelowoTL2Regular20 Mar 2025#109

Where I part company with post #105, and it is a narrow parting.

An indication approved for one age range does not extend to another, and paediatric extensions are separate decisions with separate evidence.

That is the honest state of it as of this week.

27 likes 16mo

a.ibarraTL229 Mar 2025#116

I had written a reply contradicting post #114 and deleted it. Here is what survived.

Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.

Take the reasoning and check the arithmetic; I do not always get it right.

30 likes 16mo

ne.laurentTL24 Apr 2025#121

priorauth_notes, post #31: Post #30 describes the usual case. This is about the unusual one. Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported. Go to post

Coming back to post #119, because the follow-up matters more than the original answer.

Where I would push back on the Research-use-only labelling consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

31 likes in reply to #31 16mo

Read the full topic (159 posts)

Moved from Independent verification by bench_notes. Category placement is not obvious from outside and getting it wrong is expected. This topic will get better answers here. The move is recorded in the public log citing R7.

Suggested topics

Topic	Participants	Replies	Views	Activity
Enforcement priorities versus written rules — does this still hold? Sourcing › Regulatory EMA MHRA compounding FDA Solved Under review Enforcement priorities versus written rules — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says,…	+36	40	37k	11mo
Second pass at: Import rules for personal quantities, by jurisdiction, dated Sourcing › Regulatory research use only personal import FDA MHRA Second pass at: Import rules for personal quantities, by jurisdiction, dated Writing it up because I had to work it out twice and would rather nobody else did. Asking what a regulator's document actually…		2	5k	11mo
Research-use-only labelling: what it means and what it does not Sourcing › Regulatory compounding research use only EMA FDA Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…	+100	110	37k	5mo
Prescription requirements and telehealth models — a second dataset Sourcing › Regulatory compounding EMA MHRA personal import On the subject in the title: Prescription requirements and telehealth models — a second dataset Working notes rather than a conclusion. Posting a small dataset on Prescription requirements and telehealth…	+87	94	1.1k	21d
Enforcement priorities versus written rules Sourcing › Regulatory FDA personal import MHRA Enforcement priorities versus written rules — setting out what I have, and where I think it stops being reliable. Asking what a regulator's document actually says, since the summaries of it disagree. I have…		2	62k	15mo

Related topics — sharing the tags EMA, research use only, compounding

Topic	Participants	Replies	Views	Activity
Pen wastage and its effect on real cost — the long version Access › Pricing formulary data table cost per milligram compounding Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. A narrow question about Pen wastage, deliberately narrow,…		2	34k	13mo
Second pass at: How to research a compound with no human data without deceiving yourself Compounds › Other compounds research use only custom synthesis needs a source mislabelling Second pass at: How to research a compound with no human data without deceiving yourself Writing it up because I had to work it out twice and would rather nobody else did. The question about research a…	+64	71	2.5k	13mo
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Eu-wide position versus national implementation: what I expected, what I…	+22	29	356	11mo
Coming back to: Payment method and the leverage it gives you, ranked Sourcing › Payments payments documentation quality research use only Payment method and the leverage it gives you, ranked — setting out what I have, and where I think it stops being reliable. A payments question, with the mechanics separated from the money. What I would like…	+21	26	43k	2d
Second pass at: Hoarding and why it makes a shortage worse Access › Shortages FDA compounding shortage Second pass at: Hoarding and why it makes a shortage worse Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…	+115	133	11k	21mo